WO2000041763A9 - Appareil et procede d'administration localisee d'un medicament dans un tissu - Google Patents

Appareil et procede d'administration localisee d'un medicament dans un tissu

Info

Publication number
WO2000041763A9
WO2000041763A9 PCT/US2000/000690 US0000690W WO0041763A9 WO 2000041763 A9 WO2000041763 A9 WO 2000041763A9 US 0000690 W US0000690 W US 0000690W WO 0041763 A9 WO0041763 A9 WO 0041763A9
Authority
WO
WIPO (PCT)
Prior art keywords
drug
catheter
vasculature
residence time
occlusive
Prior art date
Application number
PCT/US2000/000690
Other languages
English (en)
Other versions
WO2000041763A1 (fr
Inventor
Ascher Shmulewitz
Original Assignee
Pharmaspec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaspec Inc filed Critical Pharmaspec Inc
Publication of WO2000041763A1 publication Critical patent/WO2000041763A1/fr
Publication of WO2000041763A9 publication Critical patent/WO2000041763A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22051—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for with an inflatable part, e.g. balloon, for positioning, blocking, or immobilisation
    • A61B2017/22065—Functions of balloons
    • A61B2017/22067—Blocking; Occlusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M2025/0001—Catheters; Hollow probes for pressure measurement
    • A61M2025/0002—Catheters; Hollow probes for pressure measurement with a pressure sensor at the distal end
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0043—Catheters; Hollow probes characterised by structural features
    • A61M2025/0057—Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/1011—Multiple balloon catheters
    • A61M2025/1015—Multiple balloon catheters having two or more independently movable balloons where the distance between the balloons can be adjusted, e.g. two balloon catheters concentric to each other forming an adjustable multiple balloon catheter system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector

Definitions

  • the present invention provides a tissue localized drug delivery apparatus and method for locally administering a drug substance(s) to a specific vascular bed.
  • the localized drug delivery device for localized drug delivery comprises an occlusive means and a drug delivery means, wherein the occlusive means provides for a period of holding a high concentration of drug within a defined vascular space before release into the general circulation and significant dilutive effects of any drug remaining in the defined vascular space.
  • the localized drug delivery process provides for increased residence time ( T) and control of drug pharmacokinetics and pharacodynamics of the drug substance within a defined vasculature or tissue, particularly within the central nervous system (CNS), the heart or any vascular location containing proliferaive tissue.
  • T residence time
  • CNS central nervous system
  • the present invention further provides a localized drug delivery device and process for CNS drug delivery for augmented tissue delivery across the CNS blood brain barrier (BBB), wherein the occlusive means is located distal to a catheter drug delivery means to form a region of high drug concentration on the venous side of a CNS vascular bed with increased drug residence time before dilutive wash-out.
  • BBB blood brain barrier
  • Patent 4,689,041) with a catheter with an inflatable balloon on its distal end for insertion into the venous side of coronary vasculature that is ischemic due to impaired flow on the arterial side.
  • Aldea U.S. Patent 5,533,957 provides yet another catheter-based device for retrograde perfusion delivery of therapeutic agents to the venous side of ischemic coronary vasculature due to coronary artery obstruction by a multiple-channeled catheter device.
  • each of the two foregoing devices is targeted for venous retrograde delivery of drugs to ischemic myocardial tissue cause by coronary artery obstruction.
  • localized drug delivery means injecting a particular drug directly to the target tissue, such as an intramuscular injection of a gene therapy product directly into the myocardium to provide for local uptake of the naked DNA and (hopefully) transient expression of the gene product of the administered DNA.
  • a drug compound is physically entrapped inside a solid polymer that is then injected systemically throughout the body (not local delivery) or physically implanted in the body.
  • Other delivery systems such as intelligent delivery systems, are delivered systemically and then use a targeting agent (such as a monoclonal antibody or antibody fragment) to seek out and bind to target organs and target cells.
  • a targeting agent such as a monoclonal antibody or antibody fragment
  • the present invention provides a device and process for increasing drug residence time (RT) within a target vascular bed, comprising an occlusive means for blocking blood flow on the venous side of the target tissue vascular bed and a means for immediate-release or sustained- release delivery of the drug located within the arterial or venous side of the vascular bed, wherein the means for immediate-release drug delivery is a catheter having a tip, and the means for sustained-release drug delivery is a biodegradable polymer having drug substance embedded therein or a catheter device communicating with a sustained infusion pump, such as an osmotic pumping device.
  • RT drug residence time
  • the occlusive means comprises a balloon element of a catheter having a port for inflating and deflating the balloon, wherein the balloon element is placed proximal to the tip of the catheter.
  • the present invention provides a process for local administration of a therapeutic agent(s) to target tissues in specific vascular beds through local retrograde perfusion flow of selected target tissue, wherein the retrograde perfusion flow allows high drug concentrations across a target tissue vasculature capillary bed.
  • the present invention provides a process for increased residence time of a drug substance within vasculature of a target tissue, comprising (a) inserting an occlusive means distally to the vasculature of the target tissue, (b) inserting a catheter having an exit tip within the vasculature of the target tissue proximal to the occlusive means, (c) activating the occlusive means to occlude flow, and (d) infusing drug substance through the exit tip of the catheter.
  • the occlusive means is an inflatable balloon.
  • the occlusive means is located within the vasculature of the target tissue in a more distal location.
  • the occlusive device is located from about 2 cm to about 20 cm distal from the exit tip of the catheter.
  • the drug substance is infused through the exit tip of the catheter by means of manual infusion or infusion pumping through an entry port of the catheter.
  • the present invention further provides a process for increased residence time and increased duration of a drug substance within vasculature of a target tissue, comprising (a) inserting an occlusive means distally to the vasculature of the target tissue, wherein the occlusive means is capable of forming a conical shape having an outer surface oriented in a proximal direction (meaning facing a direction away from flow toward the heart), and further comprises drug substance(s) contained within a biodegradable matrix coated onto the outer surface of the occlusive means, (b) activating the occlusive means to occlude flow and causing drug substance to diffuse from the polymeric matrix, and (c) removing the occlusive means after completion of drug treatment.
  • the present invention further provides a drug delivery catheter for increasing drug residence time (RT) within a target vascular bed, comprising (a) a plurality of ports including a flow conduit port, and an occlusive means port, (b) an introducer sheath, (c) an occlusive means, and (d) a catheter tip, wherein the occlusive means is located in an adjustable range of from about 2 cm to about 20 cm from the catheter tip.
  • the drug delivery catheter further comprises a pressure transducer port wherein a pressure transducer is inserted at or near the catheter tip.
  • the introducer sheath is from about 6 to about 8 French.
  • the occlusive means is a balloon device that is inflated or deflated through the occlusive means port.
  • the present invention further provides drug delivery device for increasing drug residence time (RT) and duration within a target vascular bed, comprising (a) a metallic sheet formed into a cone, sphere or elliptical shape and wrapped around a delivery catheter having an outer surface and an inner surface, wherein the metallic sheet further comprises a collapsible sheet and cable allowing for insertion of the device into the target vascular bed and spreading of the shape to occlude the vein or artery when activated; and (b) drug substance(s) contained within a polymeric matrix and deposited on the outer surface of the metallic sheet.
  • RT drug residence time
  • Figure 1 shows a schematic diagram of the vasculature of target tissue 4 having two venous drainage exits 7, 8.
  • FIG. 2 shows a schematic illustration of the vasculature of target tissue 4 with atherosclerotic disease having two venous drainage exits 7, 8. There is blockage from atherosclerosis in the arterial side in the main artery feeding the tissue 10 and after its bifurcation 11.
  • Figure 3 shows a schematic diagram of the target tissue vascular flow, according to the present invention, having blockages on the venous side.
  • the drug delivery device is placed in one of the venous drainage outflows.
  • the blockage device increases the resistance to flow through vein 4.
  • Figure 4 shows the schematic diagram of the vascular bed of the target tissue having a catheter 14 inserted through the venous tree.
  • Inventive blocking device 15 is placed in vein 7 and a perfusion catheter tip 17 is placed as close as possible 16 to tissue 4.
  • Figure 5 shows the catheter 14 configure for human use having a side 6-8 Fr introducer sheath with a thin wall to allow high flow.
  • the introducer sheath has multiple ports (at least two) for inserting the perfusion catheter, to flush the system and serve as the flow conduit.
  • the drug is injected through the catheter tip 14.
  • Figure 6 shows an inventive device 21 with a metallic sheet preloaded in the shape of a cone tightly wrapped around a delivery catheter.
  • the present invention provides a method for local administration of therapeutic agents to target tissues in specific vascular beds through local high drug concentrations that get significantly diluted out after wash out into the general systemic circulation.
  • the inventive local drug delivery device provides locally high concentrations of a single or plurality of drug products either across a capillary bed of a target tissue, such as a solid tumor mass, or within more accessible venous vasculature.
  • the present invention provides a localized drug delivery device and method for drug delivery for augmented tissue delivery, such as across the CNS blood brain barrier (BBB), comprising a plugging means and a catheter drug delivery means, wherein the activation of the plugging means (such as inflation of a balloon catheter) forms a region of high drug concentration on the venous side of a vascular bed with increased drug residence time before dilutive wash-out (such as when the balloon catheter is disinflated).
  • the plugging means is a balloon-tipped catheter and causing the plugging means to plug is accomplished by inflating the balloon element of the balloon tipped catheter.
  • the method involves infusing drug material at the time when the plugging means is activated.
  • the present invention provides a venous occlusive device with a drug delivery device distal (that is, closer to the flow to the heart) to the means for blocking blood flow (i.e., venous occlusive device) to provide a temporary perfusion blockage.
  • the present invention provides a device for drug delivery to the vasculature of a target tissue.
  • the inventive device comprises a passive plugging means designed for plugging the venous tree of the vasculature of the target tissue and a catheter for immediate drug delivery or a biodegradable polymer implanted for sustained-release drug delivery.
  • sustained drug deliver can also be achieved by a catheter device having an osmotic pumping means to provide for sustained drug delivery through the end of the catheter.
  • FIG. 1 a typical vasculature tree of a target tissue 4 is shown.
  • This design has a main artery 1 with two primary branches 2, 3 that may divide into additional branches and supply oxygenated blood to the tissue 4 through a series of capillaries (not shown).
  • the capillaries are connected to venules (not shown) that drain into larger veins 5.
  • the drainage of blood is done through a network of multiple veins and shunts 6, 9 that connect between these veins. Shunts, such as 9, connect through collateral drainage networks 8.
  • Figure 2 shows the same vascular network as Figure 1 with the addition of atherosclerotic disease in the arteries.
  • the disease 10 can occur in a main artery 1 or create a partial occlusion 11 in a branch 2.
  • Collateral vessels (not shown) are created over time even with complete blockage 10.
  • Traditional drug delivery techniques are employed on the arterial side and they must assume that a collateral network created is sufficient to supply tissue 4. Most drug substance released, however, is washed out to other organs.
  • Figure 3 shows the inventive process, wherein a blockage is created on the venous side.
  • the venous side blockage increases the resistance to flow through within target tissue 4.
  • the net result is that any drug substance contained within the blood within tissue 4 during the time of venous side blockage will have vastly increased residence time within tissue 4.
  • the longer the residence time (RT) the greater the drug effectiveness because this allows for greater tissue uptake.
  • the more distal the blockage site this means closer to the heart, or larger veins), the greater the increasing RT effect.
  • blockage 13 increases RT of drugs located within capillaries in all regions of tissue 4, whereas blockage 12 has a more limited effect on only a small region of tissue 4.
  • a catheter 14 is inserted through the venous tree (preferably under some form of imaging, many such processes are widely practiced).
  • An occluder means 15 is placed in vein 7 and a perfusion catheter tip 17 is placed as close as possible 16 to target tissue 4. This allows for increased RT within target tissue 4 and for having the tip of the perfusion catheter deliver drug substance to target tissue 4 with much higher concentrations than in the general circulation and with significantly increased RT.
  • Figure 5 shows a preferred embodiment for human use.
  • the essential components of the inventive localized drug delivery catheter are multiple catheter ports for (1) inserting the localized drug delivery catheter, (2) a port for flushing the localized drug delivery catheter, and (3) a port to serve as a flow conduit.
  • the inventive localized drug delivery catheter comprises an introducer sheath with a thin wall to induce high flow.
  • the introducer sheath is from about 6 to about 8 French (one French or Fr is 0.33 mm).
  • the inventive localized drug delivery catheter further comprises an occluder means 15 for blockage of blood flow within a blood vessel, preferably a more distal vein.
  • the occluder means is a balloon connected to a side port (not shown in Figure 5) for inflation and deflation to control the occluder means.
  • the inventive localized drug delivery catheter further comprises a catheter end 14 perfusion means for injection of the drug substance(s). Drug injection can be done manually through an inj ection port, or if longer times of administration are required, an external flow pump can be administered.
  • a pressure sensor is inserted in one of the channels of the catheter 14 (not shown).
  • the location of the pressure sensor is preferably as close to the tip 16 as possible.
  • the occluder means is mounted on the same catheter as the perfusion means, as this configuration enables an increase in size of the perfusion means.
  • the occlusion means e.g., balloon
  • the occlusion means can be adjusted within a range of distances to provide for a custom fit of the target tissue venous vasculature based upon angiographic images.
  • An integrated drug delivery device for localized drug delivery having a drug delivery mechanism proximal to the occlusive means can be, for example, a catheter that is implanted as shown in Figure 4.
  • a second means for a drug delivery device is a biodegradable matrix impregnated with drug and implanted in relation to the local tissue vascular bed to be treated as shown in Figure 6.
  • the drug release from the implanted device will reach high concentrations in the immediately adjacent tissue and the vaso-vasorum of the adjacent arteries.
  • CNS administration further increases in venous pressures and residence time of the released drugs will further assist in transport across the blood brain barrier.
  • the inventive localized drug delivery catheter 21 is in the form of a "conical" embodiment.
  • the conical embodiment (which encompasses spherical shapes and elliptical shapes as well) is specifically designed for sustained release of drug substance in the form of drug contained within a biodegradable polymeric matrix.
  • the conical inventive localized drug delivery device embodiment comprises an occlusive means in the form of a metallic sheet preloaded in the shape of a cone that is tightly wrapped around a delivery catheter 24.
  • the conical embodiment has a small opening 23 that is directed, when inserted, toward a distal vein and the shaft of the catheter 24.
  • the conical element is held in place on the inventive localized drug delivery device by a collapsible cap 26 and cable 25.
  • a retrieval system (not shown in Figure 6) can be used to remove the device after completion of treatment.
  • the conical embodiment device self-expands to tightly fit the walls of vein 18.
  • the surface area of the conical element facing the vein side 20 (closer to target tissue 4) is coated with drug substance in a polymeric matrix to create a large surface area exposed to blood that has a long RT within target tissue 4. The flow distally (toward the heart and away from target tissue 4) is restricted.
  • Drug delivery through polymeric coating of stents is well known in the art.
  • anti-restenosis drugs added to bioactive or bioinert coating polymeric materials that are applied onto metallic stents via electrochemical surface polymerization in a hydrophilic solvent.
  • Stent adherence is preferably improved by pre-treating the metallic stent with a chemical treatment to roughen the surface.
  • Similar techniques as those used for stents can add a layer of drug substance to the conical embodiment of the inventive localized drug delivery device.
  • the drug substances most suitable for localized administration with the conical embodiment of the inventive localized drug delivery device include cancer chemotherapeutic agents that are highly toxic to all rapidly- dividing cells, and molecules with poor bioavailability, such as polypeptides.
  • the target tissue is a solid tumor mass and the drug or drugs impregnated in the solid matrix are drugs having a mechanism of action of being cytotoxic to rapidly dividing cells.
  • the device can be located on either the arterial side or the venous side of a target vascular bed.
  • the CNS there are tight junctions between endothelial cells that are pronounced in the arterial vasculature and even across capillary beds. This gives rise to the blood brain barrier (BBB).
  • BBB blood brain barrier
  • RT drug residence time
  • An additional advantage of the present invention is the ability to deliver drugs embedded within polymeric systems into tissue at a controlled rate or in response to physiologic or disease specific triggers.
  • a catheter can deliver a bioresponsive polymer delivery system into a tissue vasculature.
  • an immediate release catheter with a distal plugging means that perfuses immediate release perfusing agents (instead of drug substances) that act to release drug from the previously implanted polymer.
  • the target tissue is a solid tumor mass and the drug or drugs are drugs having a mechanism of action of being cytotoxic to rapidly dividing cells.
  • Either embodiment of the invention is better suited for solid tumor therapy wherein highly cytotoxic drugs that tend to be cytotoxic for rapidly dividing cells in general, are infused either in a rapid release or a sustained release schedule.
  • An immediate release means of such drug(s) causes a slight retrograde flow within the tumor tissue vasculature, combined with some hydrostatic pressure exerted on the now closed vasculature of a targeted tumor mass, will create locally high concentration of cytotoxic drug within the vasculature of the tumor mass and across its capillary beds.
  • the plugging means is a balloon catheter and causing the plugging means to plug is accomplished by inflating the balloon element of the catheter.
  • the method involves infusing drug material at the time when the plugging means is activated.
  • thrombolytic therapy for example, a catheter, would infuse a thrombolytic agent (such as a clot-dissolving enzyme such as tPa or streptokinase) selectively to the perfusion bed of the obstructed artery.
  • a thrombolytic agent such as a clot-dissolving enzyme such as tPa or streptokinase
  • a thrombolytic agent such as a clot-dissolving enzyme such as tPa or streptokinase
  • the pump means communicating with one or a plurality of channels within the catheter can be standard intravenous infusion pump using an external power source and commonly found in hospitals and clinics, or it can be a pump micromotor and housed within the catheter.
  • a pressure sensor is optionally coupled to a second or third channel within the catheter.
  • the channel designated for monitoring pressure may contain a pressure transducer which converts the blood pressure at the transducer tip located within the closed segment of target tissue vasculature between the distal plugging means and the proximal catheter, into a readable output signal. If the readable output signal indicates a pressure reading that meets or exceeds a preset safety pressure limit (for example 35 mm Hg), the pressure sensor automatically signal the pumping means to shut down until pressure is reduced. Alternatively, a low-pressure reading will likely indicate failure of the plugging means.
  • a preset safety pressure limit for example 35 mm Hg

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Anesthesiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Surgical Instruments (AREA)

Abstract

L'invention concerne un dispositif d'administration localisée d'un médicament dans un tissu, ainsi qu'un procédé d'administration locale d'un médicament dans un lit vasculaire spécifique. Ce dispositif comprend des moyens d'occlusion (15) et un moyen d'administration de médicament (14). Ce moyen d'occlusion (15) assure un temps de rétention d'un produit à forte concentration dans un espace vasculaire défini (4) avant d'être libéré dans la circulation générale, et des effets significatifs de dilution du médicament restant dans l'espace vasculaire défini (4). De manière spécifique, le processus d'administration de médicament localisée assure un temps de rétention supérieur, un contrôle de la pharmacocinétique des médicaments et la pharmacodynamique du médicament dans un système vasculaire ou un tissu défini, en particulier, dans le système nerveux central, le coeur ou dans tout emplacement vasculaire renfermant des tissus prolifératifs.
PCT/US2000/000690 1999-01-11 2000-01-11 Appareil et procede d'administration localisee d'un medicament dans un tissu WO2000041763A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22825799A 1999-01-11 1999-01-11
US09/228,257 1999-01-11

Publications (2)

Publication Number Publication Date
WO2000041763A1 WO2000041763A1 (fr) 2000-07-20
WO2000041763A9 true WO2000041763A9 (fr) 2001-11-29

Family

ID=22856424

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/000690 WO2000041763A1 (fr) 1999-01-11 2000-01-11 Appareil et procede d'administration localisee d'un medicament dans un tissu

Country Status (1)

Country Link
WO (1) WO2000041763A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689041A (en) * 1984-01-20 1987-08-25 Eliot Corday Retrograde delivery of pharmacologic and diagnostic agents via venous circulation
US5078725A (en) * 1989-11-09 1992-01-07 C. R. Bard, Inc. Balloon catheter and techniques for dilating obstructed lumens and other luminal procedures
US5304121A (en) * 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5882334A (en) * 1995-12-04 1999-03-16 Target Therapeutics, Inc. Balloon/delivery catheter assembly with adjustable balloon positioning

Also Published As

Publication number Publication date
WO2000041763A1 (fr) 2000-07-20

Similar Documents

Publication Publication Date Title
US8066690B2 (en) Method for delivering medication into an arterial wall for prevention of restenosis
US6210392B1 (en) Method for treating a wall of a blood vessel
US6102904A (en) Device for injecting fluid into a wall of a blood vessel
JP6496692B2 (ja) 閉塞灌流カテーテル
US6997898B2 (en) Multi-balloon drug delivery catheter for angiogenesis
ES2314241T3 (es) Dispositivo con una parte expansible para la liberacion de farmacos.
CZ11696A3 (en) Catheter
KR20010052377A (ko) 치료용 물질을 압력 조절에 의해 선택적으로 전달시키는방법 및 캐뉼라
EP0536296A1 (fr) Procede et catheter pour administration intravasculaire de medicaments
JPH0751379A (ja) 注入カテーテル及び脈管内部位処置方法並びにカテーテル製造方法
WO2003006096A1 (fr) Catheter de controle de circuit d'ecoulement a structure dilatable en entonnoir a la partie proximale et a structure tubulaire a la partie distale et systeme de perfusion dote d'un tel catheter
CA2359503C (fr) Dispositif medical gonflable muni d'elements d'injection destines a l'injection dans des zones localisees
JPH11506633A (ja) 遠位分配マニホールドを有する注入スリーブカテーテル
WO2000041763A9 (fr) Appareil et procede d'administration localisee d'un medicament dans un tissu
CN112638460B (zh) 在球囊导管系统内的球囊和使用方法
US20060015065A1 (en) Method of drug perfusion in paraaortic lymph node tumors, sheath for inserting catheter, and oxygenated blood perfusion apparatus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/4-4/4, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase